Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release

20250 citationsJournal Articlegold Open Access

Authors

Andreas Reif · Goethe University Frankfurt

Bernhard T. Baune · The University of Melbourne

Jozefien Buyze · Johnson & Johnson (Israel)

Anthony J. Cleare · King's College London

Sunny Johnson · Global Alliance of Mental Illness Advocacy Networks-Europe

Yerkebulan Kambarov · Johnson & Johnson (Israel)

Nigel Olisa

Abstract

Esketamine NS produced superior improvements in HRQoL compared with quetiapine XR, indicating positive impacts on aspects of patients' lives that matter to them, alongside clinical symptoms of TRD.

Topics & Keywords

Treatment of Major Depression Electroconvulsive Therapy Studies Neurotransmitter Receptor Influence on Behavior

Publication Details

Published in: European Psychiatry

Volume 68, Issue 1, pp. e156-e156

DOI: 10.1192/j.eurpsy.2025.10123

Field-Weighted Citation Impact: 0.00

Command Palette

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release

Authors

Abstract

Topics & Keywords

Publication Details